OTCMKTS:PARD

Poniard Pharmaceuticals Stock Forecast, Price & News

$0.06
0.00 (0.00 %)
(As of 05/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.03
$0.12
Volume145 shs
Average Volume6,258 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta1.35
30 days | 90 days | 365 days | Advanced Chart
Receive PARD News and Ratings via Email

Sign-up to receive the latest news and ratings for Poniard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PARD
CUSIPN/A
Phone206-286-2501
Employees7
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

No headlines for this company have been tracked by MarketBeat.com

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1677th out of 2,041 stocks

Pharmaceutical Preparations Industry

689th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions

What stocks does MarketBeat like better than Poniard Pharmaceuticals?

Wall Street analysts have given Poniard Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Poniard Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Poniard Pharmaceuticals' stock been impacted by COVID-19?

Poniard Pharmaceuticals' stock was trading at $0.0405 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PARD shares have increased by 43.7% and is now trading at $0.0582.
View which stocks have been most impacted by COVID-19
.

Who are Poniard Pharmaceuticals' key executives?

Poniard Pharmaceuticals' management team includes the following people:
  • Dr. Robert F. Caspari, Exec. Officer (Age 74)
  • Dr. Paul G. Abrams, Exec. Officer

Who are some of Poniard Pharmaceuticals' key competitors?

What is Poniard Pharmaceuticals' stock symbol?

Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."

How do I buy shares of Poniard Pharmaceuticals?

Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Poniard Pharmaceuticals' stock price today?

One share of PARD stock can currently be purchased for approximately $0.06.

How many employees does Poniard Pharmaceuticals have?

Poniard Pharmaceuticals employs 7 workers across the globe.

What is Poniard Pharmaceuticals' official website?

The official website for Poniard Pharmaceuticals is www.poniard.com.

Where are Poniard Pharmaceuticals' headquarters?

Poniard Pharmaceuticals is headquartered at 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114.

How can I contact Poniard Pharmaceuticals?

Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.